Brush Up on LMWH Dosing in Special Populations

February 2025

Questions still come up about how to dose low-molecular-weight heparin (LMWH) for venous thromboembolism in special populations.

We’re using a subcutaneous LMWH, such as enoxaparin, less often now that direct oral anticoagulants are usually preferred.

But when a LMWH is needed, dosing can be tricky in patients with renal impairment, with obesity, or who are underweight.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote